X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs MYLAN (US) - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON LTD   MYLAN
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
MYLAN
Dec-14
BIOCON LTD/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,1884,249-   
Low Rs3052,995-   
Sales per share (Unadj.) Rs68.71,454.8-  
Earnings per share (Unadj.) Rs7.6175.2-  
Cash flow per share (Unadj.) Rs14.0282.1-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.3723.2-  
Shares outstanding (eoy) m600.00378.37-   
Bonus/Rights/Conversions ISOI-  
Price / Sales ratio x10.92.5 436.3%   
Avg P/E ratio x98.920.7 478.3%  
P/CF ratio (eoy) x53.412.8 416.2%  
Price / Book Value ratio x8.65.0 172.6%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9001,370,471 32.7%   
No. of employees `0006.125.0 24.6%   
Total wages/salary Rs m9,3110-   
Avg. sales/employee Rs Th6,705.822,017.4 30.5%   
Avg. wages/employee Rs Th1,514.20-   
Avg. net profit/employee Rs Th736.92,652.4 27.8%   
INCOME DATA
Net Sales Rs m41,234550,436 7.5%  
Other income Rs m2,062-3,209 -64.3%   
Total revenues Rs m43,296547,228 7.9%   
Gross profit Rs m8,291136,896 6.1%  
Depreciation Rs m3,85140,427 9.5%   
Interest Rs m61523,743 2.6%   
Profit before tax Rs m5,88769,518 8.5%   
Minority Interest Rs m213-285 -74.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,923 53.7%   
Profit after tax Rs m4,53166,309 6.8%  
Gross profit margin %20.124.9 80.8%  
Effective tax rate %26.74.2 633.8%   
Net profit margin %11.012.0 91.2%  
BALANCE SHEET DATA
Current assets Rs m41,486483,906 8.6%   
Current liabilities Rs m21,413378,318 5.7%   
Net working cap to sales %48.719.2 253.8%  
Current ratio x1.91.3 151.5%  
Inventory Days Days6478 81.9%  
Debtors Days Days94107 87.8%  
Net fixed assets Rs m50,661127,342 39.8%   
Share capital Rs m3,00019,465 15.4%   
"Free" reserves Rs m48,8080-   
Net worth Rs m51,808273,621 18.9%   
Long term debt Rs m17,898408,763 4.4%   
Total assets Rs m99,8971,102,120 9.1%  
Interest coverage x10.63.9 269.2%   
Debt to equity ratio x0.31.5 23.1%  
Sales to assets ratio x0.40.5 82.6%   
Return on assets %5.28.2 63.0%  
Return on equity %8.724.2 36.1%  
Return on capital %9.613.6 70.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m4,7100-   
CASH FLOW
From Operations Rs m6,62172,355 9.2%  
From Investments Rs m-6,840-57,061 12.0%  
From Financial Activity Rs m-2,397-19,066 12.6%  
Net Cashflow Rs m-2,612-3,772 69.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.3 Rs / USD

Compare BIOCON LTD With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare BIOCON LTD With: IPCA LABS  DIVIS LABORATORIES  ALKEM LABORATORIES  GLENMARK PHARMA  NATCO PHARMA  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Nov 21, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - NOVARTIS COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS